Drug intelligence / Profile preview

7-alpha-D-Ribofuranosyl-2-aminopurine-5'-phosphate

Development stage
Unknown
Modality
Small Molecules
01

Overview

7-alpha-D-Ribofuranosyl-2-aminopurine-5'-phosphate is a synthetic nucleotide analog and small molecule with the chemical formula C10H14N5O7P and a molecular weight of approximately 347.22 g/mol[1][2][3][8]. It is not an approved pharmaceutical drug but has been studied experimentally, particularly as a substrate or product in enzymatic reactions related to cobalamin (vitamin B12) biosynthesis. Specifically, it is involved in the activity of nicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase (CobT), which catalyzes the synthesis of alpha-ribazole-5'-phosphate from nicotinate mononucleotide and 5,6-dimethylbenzimidazole[1][6]. Additionally, computational studies have suggested that this compound may act as an inhibitor of UBE2C (ubiquitin-conjugating enzyme E2C), indicating potential research interest in oncology or cell cycle regulation[5]. However, there are no clinical trials or approved indications for this compound.

Other names
7RA7-α-D-Ribofuranosyl-2-aminopurine-5'-phosphate
02

Targets

MjCobT (Nicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase)UBE2C (Ubiquitin-conjugating enzyme E2 C)

Beyond the preview

Go deeper on 7-alpha-D-Ribofuranosyl-2-aminopurine-5'-phosphate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 7-alpha-D-Ribofuranosyl-2-aminopurine-5'-phosphate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call